Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies
Not even a full month into the new year it’s already apparent that 2012 is going to be a busy one for mergers and acquisitions among drug and biotechnology companies. Two of those deals were announced today. Biotech giant Amgen (AMGN) said it will buy cancer drug developer Micromet (MITI) for about $1.2 billion. Meanwhile Celgene (CELG) says it will acquire its own oncology specialist closely held Avila Therapeutics for $350 million. (Celgene agreed to pay up to $575 million more if certain milestones are achieved.) Both deals will be paid in cash.   The announcements follow this week’s ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here